

**DRAFT
TOXICOLOGICAL PROFILE FOR
POLYBROMINATED BIPHENYLS AND
POLYBROMINATED DIPHENYL ETHERS**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2002

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, N.E.
Mail Stop E-29
Atlanta, Georgia 30333

Background Information

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA.¹ The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on October 25, 2001 (66 FR 54014). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); and October 21, 1999 (64 FR 56792). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Hana R. Pohl, M.D., Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Stephen Bosch, B.S.
Syracuse Research Corporation, Syracuse, NY

Richard J. Amata, Ph.D
Syracuse Research Corporation, Syracuse, NY

Carol J. Eisenmann, Ph.D.
Sciences International, Inc., Alexandria, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

Peer reviewers for the second draft (pre-public comments) of the toxicological profile on polybrominated biphenyls and polybrominated diphenyl ethers are as follows:

Loren D. Koller, DVM, Ph.D.
Principal, Environmental Health and Toxicology
325 N.E. Mistletoe Circle
Corvallis, OR 97330

Larry W. Robertson, Ph.D.
Professor, Graduate Center for Toxicology
University of Kentucky
348 Health Sciences Research Building
Lexington, KY 40536

Lee R. Shull, Ph.D.
Corporate Toxicology and Risk Assessment Practice Director
Montgomery, Watson, and Harza
777 Campus Commons, Suite 175
Sacramento, CA 95825

These experts collectively have knowledge of PBBs and PBDEs' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
 1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT ARE PBBs AND PBDEs?	1
1.2 WHAT HAPPENS TO PBBs AND PBDEs WHEN THEY ENTER THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO PBBs AND PBDEs?	3
1.4 HOW CAN PBBs AND PBDEs ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN PBBs AND PBDEs AFFECT MY HEALTH?	5
1.6 HOW CAN PBBs AND PBDEs AFFECT CHILDREN?	8
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBBs AND PBDEs?	10
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PBBs AND PBDEs?	10
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	11
1.10 WHERE CAN I GET MORE INFORMATION?	12
 2. RELEVANCE TO PUBLIC HEALTH	15
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO POLYBROMINATED BIPHENYLS AND POLYBROMINATED DIPHENYL ETHERS IN THE UNITED STATES	15
2.2 SUMMARY OF HEALTH EFFECTS	18
2.3 MINIMAL RISK LEVELS (MRLs)	30
 3. HEALTH EFFECTS	37
3.1 INTRODUCTION	37
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	40
3.2.1 Inhalation Exposure	42
3.2.1.1 Death	42
3.2.1.2 Systemic Effects	43
3.2.1.3 Immunological and Lymphoreticular Effects	49
3.2.1.4 Neurological Effects	50
3.2.1.5 Reproductive Effects	50
3.2.1.6 Developmental Effects	51
3.2.1.7 Cancer	51
3.2.2 Oral Exposure	51
3.2.2.1 Death	51

3.2.2.2	Systemic Effects	94
3.2.2.3	Immunological and Lymphoreticular Effects	139
3.2.2.4	Neurological Effects	144
3.2.2.5	Reproductive Effects	147
3.2.2.6	Developmental Effects	150
3.2.2.7	Cancer	157
3.2.3	Dermal Exposure	167
3.2.3.1	Death	167
3.2.3.2	Systemic Effects	170
3.2.3.3	Immunological and Lymphoreticular Effects	175
3.2.3.4	Neurological Effects	176
3.2.3.5	Reproductive Effects	176
3.2.3.6	Developmental Effects	177
3.2.3.7	Cancer	177
3.3	GENOTOXICITY	178
3.4	TOXICOKINETICS	182
3.4.1	Absorption	183
3.4.1.1	Inhalation Exposure	183
3.4.1.2	Oral Exposure	183
3.4.1.3	Dermal Exposure	184
3.4.2	Distribution	185
3.4.2.1	Inhalation Exposure	185
3.4.2.2	Oral Exposure	186
3.4.2.3	Dermal Exposure	191
3.4.2.4	Other Routes of Exposure	191
3.4.3	Metabolism	192
3.4.4	Elimination and Excretion	196
3.4.4.1	Inhalation Exposure	196
3.4.4.2	Oral Exposure	197
3.4.4.3	Dermal Exposure	200
3.4.4.4	Other Routes of Exposure	200
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	201
3.5	MECHANISMS OF ACTION	204
3.5.1	Pharmacokinetic Mechanisms	204
3.5.2	Mechanisms of Toxicity	205
3.5.3	Animal-to-Human Extrapolations	215
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	215
3.7	CHILDREN'S SUSCEPTIBILITY	220
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	229
3.8.1	Biomarkers Used to Identify or Quantify Exposure to PBBs and PBDEs	230
3.8.2	Biomarkers Used to Characterize Effects Caused by PBBs and PBDEs	234
3.9	INTERACTIONS WITH OTHER CHEMICALS	235
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	236
3.11	METHODS FOR REDUCING TOXIC EFFECTS	238
3.11.1	Reducing Peak Absorption Following Exposure	238
3.11.2	Reducing Body Burden	239
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	240
3.12	ADEQUACY OF THE DATABASE	241
3.12.1	Existing Information on Health Effects of PBBs and PBDEs	241
3.12.2	Identification of Data Needs	244

3.12.3 Ongoing Studies	262
4. CHEMICAL AND PHYSICAL INFORMATION	265
4.1 CHEMICAL IDENTITY	265
4.2 PHYSICAL AND CHEMICAL PROPERTIES	279
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	289
5.1 PRODUCTION	289
5.2 IMPORT/EXPORT	292
5.3 USE	292
5.4 DISPOSAL	293
6. POTENTIAL FOR HUMAN EXPOSURE	299
6.1 OVERVIEW	299
6.2 RELEASES TO THE ENVIRONMENT	302
6.2.1 Air	303
6.2.2 Water	307
6.2.3 Soil	308
6.3 ENVIRONMENTAL FATE	310
6.3.1 Transport and Partitioning	310
6.3.2 Transformation and Degradation	315
6.3.2.1 Air	315
6.3.2.2 Water	316
6.3.2.3 Sediment and Soil	318
6.3.2.4 Other Media	320
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	320
6.4.1 Air	321
6.4.2 Water	323
6.4.3 Sediment and Soil	323
6.4.4 Other Environmental Media	326
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	354
6.6 EXPOSURES OF CHILDREN	357
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	358
6.8 ADEQUACY OF THE DATABASE	359
6.8.1 Identification of Data Needs	360
6.8.2 Ongoing Studies	366
7. ANALYTICAL METHODS	367
7.1 BIOLOGICAL MATERIALS	368
7.2 ENVIRONMENTAL SAMPLES	373
7.3 ADEQUACY OF THE DATABASE	378
7.3.1 Identification of Data Needs	379
7.3.2 Ongoing Studies	380
8. REGULATIONS AND ADVISORIES	383
9. REFERENCES	391
10. GLOSSARY	442
APPENDICES	

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D. INDEX	D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to PBBs - Oral	88
3-2. Levels of Significant Exposure to PBDEs - Oral	109
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	203
3-4. Existing Information on Health Effects of PBBs	242
3-5. Existing Information on Health Effects of PBDEs	243
6-1. Frequency of NPL Sites with PBB Contamination	300

LIST OF TABLES

3-1. Levels of Significant Exposure to PBBs - Oral	55
3-2. Levels of Significant Exposure to PBDEs - Oral	95
3-3. Levels of Significant Exposure to PBBs and PBDEs - Dermal	168
3-4. Genotoxicity of PBBs and PBDEs <i>In Vivo</i>	179
3-5. Genotoxicity of PBBs and PBDEs <i>In Vitro</i>	180
3-6. Ongoing Studies on the Health Effects of PBBs and PBDEs	263
4-1. Chemical Identity of Selected PBBs	267
4-2. Chemical Identity of Polybrominated Biphenyl Congeners	275
4-3. Chemical Identity of Selected PBDEs	277
4-4. Physical and Chemical Properties of Selected PBBs	280
4-5. Identified PBB Congeners in FireMaster® BP-6 and FireMaster® FF-1	282
4-6. Physical and Chemical Properties of Selected PBDEs	285
4-7. Composition of Commercial Brominated Diphenyl Ethers	288
5-1. Facilities that Produce, Process, or Use Decabromodiphenyl Ether	291
5-2. Uses of Penta-, Octa- and Decabromodiphenyl Ethers Commercial Mixtures in Resins, Polymers, and Substrates	294
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Decabromobiphenyl Ether	305
6-2. Concentrations (in pg/m ³) of Several PBDEs in Air Samples	322
6-3. Concentrations (in ng/g Ignition Loss) of Several PBDEs in Sediment and Suspended Particulate Samples	325
6-4. Tissue Levels of PBBs in Michigan Residents	331
6-5. Concentrations (in ng/g Dry Weight) of Several PBDEs in Biosolids (Sewage Sludge) and Effluent Samples	334
6-6. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Freshwater Fish Samples	335
6-7. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Marine Aquatic Species	340

6-8. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Marine Animals	343
6-9. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Human Blood Samples	349
6-10. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Human Adipose Tissue Samples	350
6-11. Concentrations (in ng/g Lipid Weight) of Several PBDEs in Human Breast Milk Samples . . .	351
7-1. Analytical Methods for Determining PBBs in Biological Materials	369
7-2. Analytical Methods for Determining PBDEs in Biological Materials	371
7-3. Analytical Methods for Determining PBBs in Environmental Samples	374
7-4. Analytical Methods for Determining PBDEs in Environmental Samples	376
7-5. Ongoing Studies on Analytical Methods for PBBs and PBDEs	381
8-1. Regulations and Guidelines Applicable to Polybrominated Biphenyls and Polybrominated Diphenyl Ethers	385